Ameriprise
INSY

Ameriprise’s Insys Therapeutics, Inc. INSY Stock Holding History

Ameriprise’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-302,039
Closed -$2.78M – 3742
2016
Q4 		$2.78M Sell
302,039
-6,919
-2% -$78.2K ﹤0.01% 2465
2016
Q3 		$3.64M Sell
308,958
-7,785
-2% -$118K ﹤0.01% 2224
2016
Q2 		$4.1M Buy
316,743
+115,976
+58% +$1.69M ﹤0.01% 2089
2016
Q1 		$3.21M Buy
200,767
+46,004
+30% +$874K ﹤0.01% 2248
2015
Q4 		$4.43M Sell
154,763
-13,984
-8% -$387K ﹤0.01% 2092
2015
Q3 		$4.8M Buy
168,747
+98,122
+139% +$3.61M ﹤0.01% 2032
2015
Q2 		$2.54M Sell
70,625
-14,823
-17% -$462K ﹤0.01% 2599
2015
Q1 		$2.48M Buy
+85,448
New +$2.26M ﹤0.01% 2482
2014
Q4 		– Sell
-30
Closed -$1K – 4747
2014
Q3 		$1K Hold
30
– – ﹤0.01% 5637
2014
Q2 		$0 Sell
30
-130
-81% -$2.1K ﹤0.01% 5715
2014
Q1 		$3K Buy
160
+115
+256% +$2.28K ﹤0.01% 4967
2013
Q4 		$1K Sell
45
-107,865
-100% -$1.5M ﹤0.01% 5036
2013
Q3 		$1.26M Buy
107,910
+106,962
+11,283% +$878K ﹤0.01% 2613
2013
Q2 		$4K Buy
+948
New +$3.47K ﹤0.01% 5208

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCP
Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ameriprise's INSY Position: Q1 2017 in Review

Ameriprise sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 302,039 shares — an estimated $2.78M sold.

Ameriprise first reported a position in INSY in Q2 2013 and held it in 14 quarters. The position peaked at $4.8M in Q3 2015. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

  • Ameriprise reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Ameriprise sold 302,039 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $2.78M.
  • Ameriprise first reported a position in Insys Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
  • Ameriprise's Insys Therapeutics, Inc. position peaked at $4.8M in Q3 2015.
  • 116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on Ameriprise's 13F filing for Q1 2017, filed 5 May 2017.